• Phase III plan laid out.

  • Our lead drug candidate cobitolimod has a new and unique mechanism of action to effectively and safely treat ulcerative colitis.

  • InDex Pharmaceuticals hosted an R&D day on December 8, 2020

Year-end Report 2020

InDex Pharmaceuticals Holding AB (publ) published its year-end report for 2020 on February 25, 2021, at 08:00 a.m. CET.


The Share